摘要
目的评价索非布韦(SOF)联合达卡他韦(DCV)对丙肝肝硬化与慢性丙肝的疗效。方法本研究为前瞻性研究。招募2015年8月到2016年7月在我院就诊的丙肝患者,均给予口服SOF 400 mg,1/d,DCV 60 mg,1/d联合治疗。根据患者的病程及肝损伤情况将其分为丙肝肝硬化组和慢性丙肝组。收集患者治疗前后的相关临床资料,利用SPSS 21.0软件进行数据分析。结果本次研究共招募121例患者,其中丙肝肝硬化患者42人。丙肝肝硬化组和慢性丙肝组之间在性别、年龄、BMI、HCV RNA水平等方面的基线情况无显著性差异(P>0.05)。丙肝肝硬化组和慢性丙肝组具有病毒学应答的比例分别为64.3%和100%。两组患者的ALT、AST、TBIL指标均有显著性下降趋势(P<0.001),ALB有显著上升趋势(P<0.001)。两组患者瞬时弹性成像值均显著下降(P<0.001)。丙肝肝硬化患者Child-Pugh评分显著下降(P<0.001)。两组患者治疗前后肾功能指标差异均无统计学意义(P>0.05)。有13.2%的患者出现轻度至中度的头疼和疲乏。结论 SOF和DCV对丙肝肝硬化及慢性丙肝患者均有较好的治疗效果。
Objective To evaluate the clinical effect of sofosbuvir combined with daclatasvir in the treatment of patients with hepatitis C virus(HCV)liver cirrhosis and patients with chronic hepatitis C. Methods In this prospective study,the HCV patients who were enrolled in our study from August 2015 to July 2016 in our hospital received oral sofosbuvir(400 mg,daily)combined with daclatasvir(60 mg,daily).According to the symptoms and the degree of liver damage,the patients were divided into HCV cirrhosis group and chronic hepatitis C group.The data gathering from the relevant clinical data of patients before and after treatment were analyzed using SPSS 21.0 software.Results A total of 121 patients were recruited into this study,including 42 patients with HCV cirrhosis.There were no significant difference between HCV cirrhosis group and chronic hepatitis C group in terms of gender,age,BMI,and HCV RNA levels(P>0.05).The virological response ratio of HCV cirrhosis group and chronic hepatitis C group were 64.3%and 100%,respectively.ALT,AST and TBIL levels of both groups were significantly decreased(P<0.001),and the ALB level had a significant upward trend(P<0.001).Transient elastography values of two groups were significantly decreased(P<0.001).Child-Pugh scores were significantly decreased in HCV cirrhosis group(P<0.001).There were no significant difference in the renal function indexes in the two groups before and after treatment(P>0.05).13.2%of the patients had adverse effects of mild to moderate headache and fatigue.Conclusion Sofosbuvir combined with daclatasvir have good therapeutic effect on patients with HCV cirrhosis and patients with chronic hepatitis C.
作者
王威
夏辉
李兵
钱凯
庄小端
WANG Wei;XIA Hui;LI Bing;QAIN Kai;ZHAUNG Xiao-duan(Department of Hepatobiliary Surgery,First Hospital of Wuhan,Wuhan,Hubei 430000;Department of Gastroenterology,Nanfang Hospital袁Southern Medical University,Guangzhou,Guangdong 510000)
出处
《现代消化及介入诊疗》
2018年第1期18-21,共4页
Modern Interventional Diagnosis and Treatment in Gastroenterology
基金
广东省科技计划项目(2009B060700055)
关键词
索非布韦
达卡他韦
丙肝
效果
Sofosbuvir
Daclatasvir
HCV
Effectiveness
